Pune, India -- (SBWIRE) -- 12/02/2019 -- The Infinium Global Research analyzes the "Neuropathic Pain Market (Type - Phantom Limb Pain, Trigeminal Neuralgia, Post Herpetic Neuralgia, and Post-traumatic Neuropathy; Indication - Spinal Stenosis, and Diabetic Neuropathy; Diagnosis - Imaging Physical Examination, and Blood Tests; Treatment - Medication Type, NSAIDs Type, Antidepressant Drugs Type, and Multimodal Therapy; Distribution Channel - Retail Pharmacies and Drug Stores, and Online Pharmacies; End User - Hospitals, and Clinics): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025" The global neuropathic pain market is projected to grow at a CAGR of 6.1% over the forecast period of 2019-2025.

For More Details Get FREE Sample Pages of this Premium Global Report@ https://www.infiniumglobalresearch.com/reports/sample-request/13297

Growing Geriatric Population Propel Growth For Neuropathic Pain Market

The growing incidence of diabetes and cancer are the major drivers for the growth of the neuropathic pain market across the globe. According to the International federation diabetes federation, around 420 million adult population were suffering from diabetes in 2016 and is expected to reach 625 million by 2040. Furthermore, the increase in the geriatric population also fuels the growth of market growth. Furthermore, increasing healthcare expenditure are the other factors propelling market growth. Besides, growing awareness among patients for the treatment of neuropathic pain also fuels the growth of the neuropathic pain market. However, growing counterfeit drugs, side effects of treatments and lack of awareness about the neurological condition restrain the growth of the market. Moreover, well-established reimbursements and strong healthcare infrastructure create an opportunity for the growth of the global neuropathic pain management market in the upcoming years.

Antidepressant Drugs Anticipated Growth at a Rapid Pace Over the Forecast Period

The global neuropathic pain market has been classified based on type, indication, diagnosis, treatment, distribution channel, and end-user. Based on type, the market has been divided into phantom limb pain, trigeminal neuralgia, postherpetic neuralgia, and post-traumatic neuropathy. By indication, the market is fragmented into spinal stenosis and diabetic neuropathy. In terms of diagnosis, the market is segmented into imaging physical examination and blood tests.

The imaging market segment is further sub-segmented into electromyography, MRI, and CT. Based on treatment, the market is bifurcated into medication type, NSAIDs type, antidepressant drugs type, and multimodal therapy. NSAIDs types are further segmented into naproxen, ibuprofen, and others. Antidepressant drug type is further segmented into tricyclic antidepressants and serotonin noradrenaline. In terms of distribution channels, the market is categorized into retail pharmacies & drug stores and online pharmacies. Based on end-user, the market is divided into hospitals and clinics.

Ask Discount for the Latest Research Report @ https://www.infiniumglobalresearch.com/reports/request-discount/13297

Rising Geriatric Population Dominates the Region of North America

Geographically, the global market for neuropathic pain has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is leading the neuropathic pain market due to an increase in the elderly population, which leads to too many disorders and diseases. Furthermore, a strong distribution network, presence of advanced healthcare infrastructure and major players of the market in the region are some other factors that help the growth of the market in the North American region.

The European market is projected to be the second-largest during the forecast period. This is primarily due to the increasing cases of cancer patients in the region. The Asia Pacific is projected to grow at a faster rate due to the increasing frequency of diabetes in countries such as India and China.

Neuropathic Pain Market: Company landscapes

The global neuropathic pain market comprises with the players such as Johnson & Johnson Services Inc., Pfizer Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi S.A., Biogen Idec Inc., Baxter Healthcare Corporation, and Depomed Inc.

Browse Complete Global Report and Detailed TOC: https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-neuropathic-pain-market  

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of the neuropathic pain.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2025.

=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.  

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.